reason report
strong close year guid rais
bottom line deliv strong rais
guid prior estim y/i
growth believ stock trade higher reflect
solid quarter rais guid still appear conserv
backdrop percepta biopharma revenu ramp afirma
lead test drove anoth strong test
estimate percepta test deliv test
highlight grow momentum believ guidanc like
proven conserv afirma genom sequenc classifi
gsc continu penetr account deeper superior featur
data vs gene express classifi gec beyond see
percepta reorder rate rise biopharma revenu op
loxo collabor continu deliv hope attain cash
flow break-even ye maintain op rate rais pt
percepta remain key long-term upsid percepta deliv
test continu momentum last quarter sale rep
carri percepta afirma bag manag
execut believ key deepen penetr percepta
alreadi receiv final posit local coverag determin lcd
expect commerci reimburs percepta level
afirma longer term model
penetr percepta year-end
envisia remain earli afirma adopt still room grow
number thing drove afirma adopt importantli
believ deepen account includ uptak new
improv afirma gsc broader reimburs penetr
afirma believ still room grow physician
continu reorder test asp expect increas
guid rais reflect momentum rais revenue guid
 think still conserv
given potenti upsid includ percepta adopt
collabor biopharma revenue ramp increas asp across
afirma percepta envisia start see sale ahead
medicar commerci reimburs higher-margin product
servic mix expect off-set increas management also expect
break even cash flow op ye
life scienc tool diagnost
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
collabor innov jnj global lung cancer initi
develop novel non-invas earli stage nasal swab diagnost test
lung cancer valid potenti vcyt field injuri tech
part collabor receiv jan
futur revenu clinic studi grow believ collabor
valid lt potenti nasal swab field injuri test
clariti magnitud upsid present data
beyond
rate share outperform price target
address company-estim diagnost market via neg classifi test help
reduc ambigu diagnosi sizabl subset thyroid lung cancer patient well
dramat reduc unnecessari surgeri vcyt test improv diagnosi save
healthcar cost believ pose signific valu provid payer
value-driven healthcar landscap develop proprietari express test
afirma identifi benign thyroid nodul indetermin tradit cytolog help
physician patient confid forgo unnecessari thyroid surgeri afirma believ
path becom standard care given thyroid fna
fine needl aspir found indetermin year suitabl test
afirma alreadi driven near penetr market compani expect
reach longer term company-estim market market
veracyt second test percepta bronchial gene express classifi
neg predict valu help identifi patient consid low risk initi
bronchoscopi result found inconclus help reduc unnecessari surgeri
save overal cost system percepta bronchial classifi address
bronchoscopi everi year lung nodul reveal ct inconclus
case drive market opportun percepta test
annual market reimburs medicar continu garner
also commerci envisia third test neg classifi test idiopath
pulmonari fibrosi ipf drive total address market three diagnost test
believ reimburs continu import driver revenu
beyond test volum compani continu build stronger payer base time
gain increasingli cover contract live drive adopt test
vcyt multi-year collabor innov earli stage discoveri therapeut arm
global lung cancer initi develop non-invas nasal swab diagnost
test lung cancer valid potenti field injuri approach posit
part collabor receiv payment addit
follow futur clinic studi grow expect gain view potenti
test present data beyond -- like start american thorac
societi at may
multipl shot goal prove technolog model address
inconclus biopsi longer term believ adopt vcyt gene express
test cancer thyroid nodul lung bronchi continu increas
data reimburs updat pipelin offer addit catalyst addit believ
vcyt manag team includ ceo bonni anderson proven execut
ramp maxim revenu shift reimburs landscap
share current trade ev/sal slightli diagnost peer
qtnt ghdx ttoo multipl averag given higher rate
reimburs newli launch test gain traction back strong clinic data
biopharma revenu ramp believ share could trade turn group multipl
ev/sal estim result pt
primari risk price target includ limit reimburs
rate decis move forward visibl test includ percepta envisia fda
regul financ commit given neg cash flow near term
declin reimburs could sever impact revenu major risk
reimburs rate could decreas dramat current reimburs rate
among highest industri much revenu base
reimburs rate impact amount test administ adopt rate
exist new test vcyt ramp would sever impact refil reject
even wors reimburs rate continu fall given still early-stag compani
visibl still somewhat limit despit encourag sign still early-stag
compani neg net incom provid progress report afirma
encourag result test gain traction howev still plenti uncertainti
busi given model still show neg earn least busi
develop forecast expect face challeng new compani face
competit disadvantag limit visibl
fda regul remain risk regulatori concern fda decis
impact product still earli stage ramp envisia
could impact fda given nascent natur test fda regul could impact
product number product offer compani increas regul
fda would requir addit sg expens satisfi complianc increas cost
could also affect abil ramp
addit financ could still happen posit cash flow come later expect
possibl may need addit financ given expect neg net incom
near term expect posit cash flow come later expect compani
need anoth round financ exist debt could lead addit interest expens
increas net debt balanc sheet could also lead increas capit cost
servic
interest expens incom net
sg sale
 sale
oper expens sale
compani report svb leerink estim
